menu
    • menu
    [{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pierre Fabre \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pierre Fabre \/ Not Applicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Erasca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Erasca","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Erasca"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"EORTC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Encorafenib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pierre Fabre \/ EORTC","highestDevelopmentStatusID":"10","companyTruncated":"Pierre Fabre \/ EORTC"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"European Organisation for Research and Treatment of Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pierre Fabre \/ European Organisation for Research and Treatment of Cancer","highestDevelopmentStatusID":"10","companyTruncated":"Pierre Fabre \/ European Organisation for Research and Treatment of Cancer"},{"orgOrder":0,"company":"Erasca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Erasca \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Not Applicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Cetuximab","moa":"WEE1","graph1":"Oncology","graph2":"Preclinical","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Zentalis Pharmaceuticals \/ Pfizer","highestDevelopmentStatusID":"4","companyTruncated":"Zentalis Pharmaceuticals \/ Pfizer"},{"orgOrder":0,"company":"Erasca","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Erasca \/ Pierre Fabre","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Pierre Fabre"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Erasca \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Not Applicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Foundation Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Foundation Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Encorafenib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Foundation Medicine \/ Pierre Fabre","highestDevelopmentStatusID":"10","companyTruncated":"Foundation Medicine \/ Pierre Fabre"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pierre Fabre \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pierre Fabre \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Encorafenib

    Menu

    Encorafenib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    Ă—
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Foundation Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Foundation Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Encorafenib,Binimetinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Pierre Fabre

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Foundation Medicine Announces Collaboration with Pierre Fabre Laboratories to Develop Companion Diagnostics in...

                            Details : The companies will work to seek the regulatory approval for Foundation Medicine assays which detect mutations including BRAFV600E to identify patients for potential treatment with Pierre’s BRAF/MEK inhibitor, BRAFTOVI (encorafenib) and MEKTOVI (binimet...

                            Brand Name : Braftovi

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 15, 2023

                            Lead Product(s) : Encorafenib,Binimetinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Pierre Fabre

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pierre Fabre

                            France arrow
                            BMWS24
                            Not Confirmed

                            Pierre Fabre

                            France arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Encorafenib,Binimetinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            European Medicines Agency Validates Pierre Fabre Laboratories' Marketing Authorisation Application for Combina...

                            Details : Braftovi (encorafenib) + Mektovi (binimetinib) is approved for the treatment of adult patients with BRAFV600-mutant advanced non-small cell lung cancer (NSCLC), who are either treatment naĂŻve or have received prior therapy.

                            Brand Name : Braftovi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 02, 2023

                            Lead Product(s) : Encorafenib,Binimetinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pfizer Inc

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Pfizer Inc

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Encorafenib,Binimetinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cance...

                            Details : Braftovi (Encorafenib) is an oral small molecule BRAF kinase inhibitor and is approved in combination with Mektovi (binimetinib) in patients with BRAF V600E-mutant metastatic non-small cell lung cancer.

                            Brand Name : Braftovi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 12, 2023

                            Lead Product(s) : Encorafenib,Binimetinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Foundation Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Foundation Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Encorafenib,Cetuximab,Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            U.S. Food and Drug Administration (FDA) Approves FoundationOneLiquid CDx as a Companion Diagnostic for Pfizerâ...

                            Details : Braftovi (Encorafenib) Is An Oral Small Molecule Braf Kinase Inhibitor And Combination With Cetuximab Used for Patients With Patients With Braf V600E Alterations In Metastatic Colorectal Cancer.

                            Brand Name : Braftovi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 09, 2023

                            Lead Product(s) : Encorafenib,Cetuximab,Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Erasca

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Erasca

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ERAS-007,Encorafenib,Cetuximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

                            Details : ERAS-007 is an oral ERK1/2 inhibitor. ERAS-007 + EC was generally well tolerated with mostly low-grade treatment-related adverse events (TRAEs) at all combination doses tested for the treatment of metastatic BRAF V600E- colorectal cancer.

                            Brand Name : ERAS-007

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 05, 2023

                            Lead Product(s) : ERAS-007,Encorafenib,Cetuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Pfizer Inc

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Pfizer Inc

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Encorafenib,Binimetinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Accepts Pfizer’s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI

                            Details : Braftovi (encorafenib) is an oral small molecule BRAF kinase inhibitor and MEKTOVI (binimetinib) is an oral small molecule MEK inhibitor which target key proteins in the MAPK signaling pathway (RAS-RAF-MEK-ERK), for patients with metastatic non-small cel...

                            Brand Name : Braftovi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 04, 2023

                            Lead Product(s) : Encorafenib,Binimetinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Erasca

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Erasca

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ERAS-007,Encorafenib,Cetuximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Pierre Fabre

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and ...

                            Details : The agreement will support a clinical proof-of-concept trial evaluating ERAS-007, an oral ERK1/2 inhibitor, in combination with encorafenib and the anti-EGFR antibody cetuximab for the treatment of patients with BRAF V600E-mutant metastatic colorectal ca...

                            Brand Name : ERAS-007

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 30, 2022

                            Lead Product(s) : ERAS-007,Encorafenib,Cetuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Pierre Fabre

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Zentalis Pharmaceuticals

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Zentalis Pharmaceuticals

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azenosertib,Encorafenib,Cetuximab

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with Pfizer

                            Details : Zentalis and Pfizer will initiate a Phase 1/2 dose escalation study of ZN-c3 in combination with encorafenib and cetuximab—an FDA-approved standard of care known as the BEACON regimen—in patients with BRAF V600E-mutated metastatic colorectal cancer (...

                            Brand Name : ZN-c3

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 24, 2022

                            Lead Product(s) : Azenosertib,Encorafenib,Cetuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Erasca

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Erasca

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ERAS-007,Encorafenib,Cetuximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Erasca Presents Promising Preliminary Phase 1/1b Monotherapy Data for ERAS-007 ERK and ERAS-601 SHP2 Inhibitor...

                            Details : 23% (6/26) of patients with RAS/MAPK-altered non-CRC solid tumors and 44% (4/9) with BRAF-driven non-CRC solid tumors responded (confirmed and unconfirmed PR) to single agent ERAS-007 or ERAS-601.

                            Brand Name : ERAS-007

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 07, 2022

                            Lead Product(s) : ERAS-007,Encorafenib,Cetuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Pierre Fabre

                            France arrow
                            BMWS24
                            Not Confirmed

                            Pierre Fabre

                            France arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Encorafenib,Binimetinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : European Organisation for Research and Treatment of Cancer

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pierre Fabre and EORTC Open a Large Phase III Clinical Study in The Adjuvant Setting of Stage IIB-C Melanoma

                            Details : Braftovi (encorafenib) is an oral small-molecule BRAF kinase inhibitor and binimetinib is an oral small-molecule MEK inhibitor that targets key enzymes in the MAPK signalling pathway (RAS-RAF-MEK-ERK).

                            Brand Name : Braftovi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 24, 2022

                            Lead Product(s) : Encorafenib,Binimetinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : European Organisation for Research and Treatment of Cancer

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth